BOT+BAL Phase Ib OS Signal in MSS mCRC: Durable Plateau Compelling, Randomized Proof Absent

Agenus' BOT+BAL Achieves Durable Three-Year OS in Refractory mCRC

Agenus announced that its combination therapy of botensilimab (BOT) and balstilimab (BAL) demonstrated a median overall survival (OS) of 21.2 months and a three-year OS rate of 33% in a Phase Ib trial (NCT03860272) for refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). The trial enrolled 123 heavily pretreated patients who had received a median of three prior lines of therapy. These long-term survival data, presented at ESMO GI 2026, indicate a durable benefit in a patient population with historically limited treatment options and poor outcomes from conventional immune checkpoint inhibitors. The Kaplan-Meier curve showed a plateau beyond two years, supporting the therapy's sustained efficacy.

• The combination of BOT+BAL achieved a median overall survival of 21.2 months and a notable 33% three-year overall survival rate in refractory MSS mCRC patients. This represents a significant improvement over historical median OS rates of 10-14 months for approved later-line treatments, with the Kaplan-Meier curve showing a plateau beyond two years, underscoring the durable benefit of the therapy.
• The Phase Ib trial enrolled 123 patients with refractory MSS mCRC, a challenging population characterized by a median of three prior lines of therapy and limited response to conventional immune checkpoint inhibitors. The observed long-term survival and durability are particularly impactful for these patients who typically have few remaining effective treatment options.
• Beyond survival, the therapy showed a confirmed objective response rate of 21%, including three complete responses and 23 partial responses, with the median duration of response not yet reached. Importantly, 17% of patients were alive and off systemic anticancer therapy at last follow-up. The safety profile was favorable, with no new safety signals or treatment-related deaths, and immune-mediated diarrhoea/colitis resolving in 98% of affected patients.
• Building on these positive results, Agenus has initiated the Phase III BATTMAN trial for BOT+BAL in refractory, unresectable MSS or pMMR mCRC. Furthermore, Agenus recently completed a $141 million strategic collaboration with Zydus Lifesciences, granting Zydus exclusive rights to develop and commercialize BOT/BAL in Sri Lanka and India, with Agenus eligible for a 5% royalty on net sales.

Addressing the High Unmet Need in Refractory MSS mCRC

Metastatic colorectal cancer (mCRC) remains one of the most therapeutically challenging malignancies, with response rates that are low at diagnosis and decline further with each subsequent line of therapy. The convergence of tumor biological complexity, resistance mechanisms, and the limitations of current precision medicine frameworks creates a compounding unmet need — particularly in microsatellite stable (MSS) disease, where immunotherapy has largely failed to demonstrate meaningful benefit. Five-year survival rates decline rapidly upon progression to advanced metastatic disease, underscoring the urgency of addressing these gaps.

• Pervasive and multifactorial drug resistance represents the foremost barrier to durable responses in mCRC. Resistance arises through intratumoral and intertumoral heterogeneity, activation of compensatory signaling cascades (Wnt/β-catenin, Notch, Hedgehog, PI3K/Akt, and MAPK/ERK), epithelial-mesenchymal transition (EMT), enhanced DNA repair mechanisms, and PD-1/PD-L1-mediated immune evasion — mechanisms that remain incompletely characterized.

• Cancer stem cells (CSCs) drive therapy resistance, tumor initiation, and metastasis. Colorectal CSCs (CCSCs) sustain drug tolerance through core stemness pathways and transform the tumor microenvironment (TME) into a stemness-supportive, immunosuppressive niche that promotes recurrence. Chemotherapy in particular may fail to eliminate a subpopulation of aggressive, stem-like circulating tumor cells (CTCs) characterized by multidrug resistance, including those expressing ALDH1, survivin, and MRP5 — markers associated with significantly shorter progression-free survival.

• Patients harboring BRAF or RAS mutations face poor outcomes despite advances in systemic therapy. Even among RAS wild-type patients eligible for anti-EGFR monoclonal antibodies (cetuximab, panitumumab), response rates are limited to approximately 70% in combination with multidrug chemotherapy regimens, with additional resistance mechanisms — including genetic alterations and epigenetic reprogramming — continuing to emerge under therapeutic pressure.

• Standard chemotherapy backbones carry significant toxicity burdens without resolving resistance. The FOLFOXIRI combination (folinic acid, 5-fluorouracil, oxaliplatin, and/or irinotecan) inhibits tumor growth but provokes drug resistance and serious adverse effects. Drug combinations administered at clinical doses have been shown to result in significantly higher antagonistic interactions compared to low-dose optimized regimens, while optimized drug combinations (ODCs) were inactive in CRC cells chronically pretreated with FOLFOXIRI — suggesting the emergence of cross-resistance.

• The absence of robust predictive biomarkers limits treatment individualization. Not all systemic therapies have associated biomarkers capable of accurately predicting patient response. Compounding this, matched patient-derived organoids (PDOs) from primary and metastatic lesions of the same patient exhibited differential sensitivity patterns to rationally designed drug combinations despite being genetically similar — directly highlighting the limitations of current genomics-driven precision medicine in guiding treatment strategy for mCRC.

• The pronounced heterogeneity of CSCs and the lack of validated markers for their identification and therapeutic monitoring remain substantial obstacles to developing and translating CSC-directed therapies. Activation of compensatory signaling pathways upon targeted intervention further undermines the durability of any single-agent or pathway-specific approach, reinforcing the need for rational combination strategies and integrative multi-omics frameworks to delineate CSC-specific vulnerabilities.

BOT+BAL Delivers Durable Survival in Heavily Pretreated mCRC

Several high-impact trials have recently reported findings across treatment lines in metastatic colorectal cancer. The MOUNTAINEER trial (NCT03043313) evaluated tucatinib plus trastuzumab in 84 patients with chemotherapy-refractory, HER2-positive, RAS wild-type mCRC, delivering a confirmed ORR of 39.3%, median duration of response of 15.2 months, median PFS of 8.1 months, and median OS of 23.9 months at a median follow-up of 32.4 months — with no treatment-emergent deaths and few treatment discontinuations due to adverse events. The STELLAR-303 trial assessed zanzalintinib plus atezolizumab versus regorafenib in 901 patients with previously treated, non-MSI-H/dMMR mCRC, demonstrating a statistically significant OS improvement of 10.9 versus 9.4 months (HR 0.80, 95% CI 0.69–0.93; p=0.0045), marking the first phase III trial to show a meaningful OS benefit with an immunotherapy-based regimen in this population; however, grade ≥3 treatment-related adverse events were notably higher in the combination arm (60% vs. 37%). The ARC-9 study, Cohort B evaluated etrumadenant, zimberelimab, FOLFOX, and bevacizumab (EZFB) versus regorafenib in 112 third-line mCRC patients, yielding a median PFS of 6.2 versus 2.1 months (HR 0.27; p<0.0001) and median OS of 19.7 versus 9.5 months (HR 0.37; p=0.0003), with a confirmed ORR of 17% versus 3%; grade ≥3 TEAEs occurred in 82% of the EZFB arm versus 49% in the regorafenib arm, though fewer patients discontinued on EZFB (5% vs. 17%).

In the first-line RAS/BRAF wild-type setting, the TRIPLETE trial reported five-year results comparing mFOLFOXIRI plus panitumumab (n=218) to mFOLFOX plus panitumumab (n=217), showing a statistically significant OS benefit of 41.1 versus 33.3 months (HR 0.79, 95% CI 0.63–0.99; p=0.049) at a median follow-up of 60.2 months, without significant differences in ORR (78% vs. 75%), PFS (HR 0.95), or resection rates. The pooled analysis of the PanaMa (NCT01991873) and Valentino (NCT02476045) trials in 607 RAS wild-type mCRC patients receiving FOLFOX plus panitumumab induction found that panitumumab-based maintenance improved PFS in left-sided, negative hyperselected patients versus 5-FU/LV alone, with panitumumab monotherapy potentially optimizing the efficacy-toxicity balance in this subgroup. In the later-line refractory setting, a meta-analysis of nine studies encompassing 1,509 participants confirmed that TAS-102 plus bevacizumab was superior to TAS-102 monotherapy across all key endpoints — OS (HR 0.52; p<0.001), PFS (HR 0.49; p<0.001), ORR (RR 3.28; p<0.001), and DCR (RR 1.58; p<0.001) — with the benefit particularly pronounced in RAS-mutant patients and those with prior bevacizumab exposure, at the cost of increased neutropenia (grade ≥3 RR 1.38) and thrombocytopenia.

Across earlier-line and biomarker-selected populations, additional studies extend the evidence base. The ERBITAG non-interventional study (n=728, RAS wild-type mCRC) documented real-world outcomes with cetuximab-based first-line chemotherapy — median PFS 10.9 months, median OS 23.6 months, ORR 58.0%, and a liver/lung metastasis resection rate of 13.9% — with acne-like rash as the most common TEAE (all grades 46.8%; grade 3–4 4.7%), and skin prophylaxis associated with improved ORR, PFS, and OS. A phase II single-arm study of anlotinib plus trifluridine-tipiracil in 20 evaluable refractory mCRC patients demonstrated an ORR of 10.0%, DCR of 90.0%, and median PFS of 5.6 months, with a manageable safety profile and grade ≥3 TEAEs limited to neutropenia (25%) and thrombocytopenia (5%). The NSABP FC-11 trial (NCT03457896, Arm 2) tested neratinib plus cetuximab in quadruple wild-type (KRAS/NRAS/BRAF/PIK3CA) mCRC, achieving an intention-to-treat ORR/PFS6 of 28% (6/21) with no grade 5 or unexpected adverse events, though correlative molecular analyses did not definitively identify a predictive biomarker for response.

Expanding the Horizon: BOT+BAL's Broader Pipeline Potential

Beyond metastatic colorectal cancer, the BOT+BAL combination is being investigated across several solid tumor indications, reflecting the broad immunostimulatory potential of Fc-enhanced CTLA-4 blockade combined with PD-1 inhibition. Trial designs consistently employ a phase I/Ib open-label framework, with BOT dosed intravenously at 1–2 mg/kg every 6 weeks and BAL at 3 mg/kg every 2 weeks for up to 2 years.

A New Horizon for Refractory MSS Colorectal Cancer

The recent announcement regarding the botensilimab and balstilimab combination therapy in refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) marks a potentially pivotal moment for a patient population desperately in need of effective treatments. Historically, MSS mCRC has been a formidable challenge for immunotherapy, with studies consistently demonstrating limited T-cell infiltration in the tumor microenvironment and unsatisfactory responses to single-agent immune checkpoint inhibitors. For instance, the IMblaze370 trial, evaluating atezolizumab with or without cobimetinib in this setting, failed to meet its primary endpoint of improved overall survival, underscoring the inherent resistance of these tumors.

However, the reported median overall survival of 21.2 months and a three-year overall survival rate of 33% from Agenus's Phase Ib trial represent a significant departure from these historical outcomes. This durable benefit, characterized by a plateau in the Kaplan-Meier curve, suggests that the dual blockade strategy—combining botensilimab (an Fc-enhanced anti-CTLA-4 antibody) with balstilimab (an anti-PD-1 antibody)—may be effectively overcoming the immunosuppressive environment that renders MSS mCRC 'cold' to conventional immunotherapy. CTLA-4 inhibition is known to deplete regulatory T cells and enhance T-cell priming, while PD-1 inhibition releases the brakes on activated T cells. This synergistic mechanism, potentially augmented by botensilimab's Fc-enhancement, appears to re-ignite a robust anti-tumor immune response.

While these early data are highly encouraging, it is crucial to acknowledge the inherent risks associated with Phase Ib results. The findings, derived from a relatively small, heavily pretreated cohort, require validation in larger, randomized clinical trials to confirm their reproducibility and generalizability. Furthermore, combination immunotherapies, particularly those involving CTLA-4 inhibitors, are known to carry a risk of immune-related adverse events, and the long-term safety profile of this specific regimen will need careful monitoring. Identifying predictive biomarkers beyond MSS status will also be critical to optimize patient selection and ensure that the right patients receive this potentially life-changing therapy. If these promising results hold, this combination could not only redefine the treatment landscape for MSS mCRC but also provide a blueprint for overcoming immunotherapy resistance in other 'cold' tumors.